Selected research
Market Structure
Global Rotavirus Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Rotavirus Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Rotavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Rotavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Rotavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Rotavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Rotavirus Vaccine include GlaxoSmithKline Biologicals, Lanzhou Institute of Biological Products and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Rotavirus Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Rotavirus Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Rotavirus Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Rotavirus Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.
Rotavirus Vaccine Segment by Company
GlaxoSmithKline Biologicals
Lanzhou Institute of Biological Products
Merck
Rotavirus Vaccine Segment by Type
RV3
RV5
Rotavirus Vaccine Segment by Application
Government Institution
Private Sector
Other
Rotavirus Vaccine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rotavirus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rotavirus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rotavirus Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Rotavirus Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rotavirus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Rotavirus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Rotavirus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- RV3
- RV5
Applications
- Government Institution
- Private Sector
- Other
Companies covered
- GlaxoSmithKline Biologicals
- Lanzhou Institute of Biological Products
- Merck
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Rotavirus Vaccine Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Rotavirus Vaccine Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Rotavirus Vaccine Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Rotavirus Vaccine Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Rotavirus Vaccine Market Dynamics
- 2.1 Rotavirus Vaccine Industry Trends
- 2.2 Rotavirus Vaccine Industry Drivers
- 2.3 Rotavirus Vaccine Industry Opportunities and Challenges
- 2.4 Rotavirus Vaccine Industry Restraints
3 Rotavirus Vaccine Market by Manufacturers
- 3.1 Global Rotavirus Vaccine Revenue by Manufacturers (2021-2026)
- 3.2 Global Rotavirus Vaccine Sales by Manufacturers (2021-2026)
- 3.3 Global Rotavirus Vaccine Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Rotavirus Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Rotavirus Vaccine Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Rotavirus Vaccine Manufacturers, Product Type & Application
- 3.7 Global Rotavirus Vaccine Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Rotavirus Vaccine Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Rotavirus Vaccine Players Market Share by Revenue in 2025
- 3.8.3 2025 Rotavirus Vaccine Tier 1, Tier 2, and Tier 3
4 Rotavirus Vaccine Market by Type
- 4.1 Rotavirus Vaccine Type Introduction
- 4.1.1 RV3
- 4.1.2 RV5
- 4.2 Global Rotavirus Vaccine Sales by Type
- 4.2.1 Global Rotavirus Vaccine Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Rotavirus Vaccine Sales by Type (2021-2032)
- 4.2.3 Global Rotavirus Vaccine Sales Market Share by Type (2021-2032)
- 4.3 Global Rotavirus Vaccine Revenue by Type
- 4.3.1 Global Rotavirus Vaccine Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Rotavirus Vaccine Revenue by Type (2021-2032)
- 4.3.3 Global Rotavirus Vaccine Revenue Market Share by Type (2021-2032)
5 Rotavirus Vaccine Market by Application
- 5.1 Rotavirus Vaccine Application Introduction
- 5.1.1 Government Institution
- 5.1.2 Private Sector
- 5.1.3 Other
- 5.2 Global Rotavirus Vaccine Sales by Application
- 5.2.1 Global Rotavirus Vaccine Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Rotavirus Vaccine Sales by Application (2021-2032)
- 5.2.3 Global Rotavirus Vaccine Sales Market Share by Application (2021-2032)
- 5.3 Global Rotavirus Vaccine Revenue by Application
- 5.3.1 Global Rotavirus Vaccine Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Rotavirus Vaccine Revenue by Application (2021-2032)
- 5.3.3 Global Rotavirus Vaccine Revenue Market Share by Application (2021-2032)
6 Global Rotavirus Vaccine Sales by Region
- 6.1 Global Rotavirus Vaccine Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Rotavirus Vaccine Sales by Region (2021-2032)
- 6.2.1 Global Rotavirus Vaccine Sales by Region (2021-2026)
- 6.2.2 Global Rotavirus Vaccine Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Rotavirus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Rotavirus Vaccine Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Rotavirus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Rotavirus Vaccine Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Rotavirus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Rotavirus Vaccine Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Rotavirus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Rotavirus Vaccine Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Rotavirus Vaccine Revenue by Region
- 7.1 Global Rotavirus Vaccine Revenue by Region
- 7.1.1 Global Rotavirus Vaccine Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Rotavirus Vaccine Revenue by Region (2021-2026)
- 7.1.3 Global Rotavirus Vaccine Revenue by Region (2027-2032)
- 7.1.4 Global Rotavirus Vaccine Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Rotavirus Vaccine Revenue (2021-2032)
- 7.2.2 North America Rotavirus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Rotavirus Vaccine Revenue (2021-2032)
- 7.3.2 Europe Rotavirus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Rotavirus Vaccine Revenue (2021-2032)
- 7.4.2 Asia-Pacific Rotavirus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Rotavirus Vaccine Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Rotavirus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 GlaxoSmithKline Biologicals
- 8.1.1 GlaxoSmithKline Biologicals Company Information
- 8.1.2 GlaxoSmithKline Biologicals Business Overview
- 8.1.3 GlaxoSmithKline Biologicals Rotavirus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 GlaxoSmithKline Biologicals Rotavirus Vaccine Product Portfolio
- 8.1.5 GlaxoSmithKline Biologicals Recent Developments
- 8.2 Lanzhou Institute of Biological Products
- 8.2.1 Lanzhou Institute of Biological Products Company Information
- 8.2.2 Lanzhou Institute of Biological Products Business Overview
- 8.2.3 Lanzhou Institute of Biological Products Rotavirus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Lanzhou Institute of Biological Products Rotavirus Vaccine Product Portfolio
- 8.2.5 Lanzhou Institute of Biological Products Recent Developments
- 8.3 Merck
- 8.3.1 Merck Company Information
- 8.3.2 Merck Business Overview
- 8.3.3 Merck Rotavirus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Merck Rotavirus Vaccine Product Portfolio
- 8.3.5 Merck Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Rotavirus Vaccine Value Chain Analysis
- 9.1.1 Rotavirus Vaccine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Rotavirus Vaccine Production Mode & Process
- 9.2 Rotavirus Vaccine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Rotavirus Vaccine Distributors
- 9.2.3 Rotavirus Vaccine Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst